Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00137371
Collaborator
(none)
480
49
25
9.8
0.4

Study Details

Study Description

Brief Summary

This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.

Condition or Disease Intervention/Treatment Phase
  • Drug: PVC (daily for 21 days, 7 days off)
  • Drug: PVC (twice weekly)
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis
Study Start Date :
Aug 1, 2005
Actual Study Completion Date :
Sep 1, 2007

Outcome Measures

Primary Outcome Measures

  1. To evaluate the efficacy of 2 low dose regimens of conjugated estrogen in the treatment of atrophic vaginitis from baseline to 12 weeks. []

Secondary Outcome Measures

  1. To evaluate change from baseline in the percentage of superficial cells, symptom relief, the effect of both regimens on endometrial stimulation and genital health. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 80 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:

Generally healthy postmenopausal women with symptoms of atrophic vaginitis including vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse.

The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.

Exclusion Criteria:

Women who do not have a clinical diagnosis of atrophic vaginitis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tucson Arizona United States 85715
2 Encinitas California United States 92024
3 San Diego California United States 92108
4 Torrance California United States 90502
5 Aurora Colorado United States 80010
6 Brooksville Florida United States 34613
7 Miami Florida United States 33186
8 St. Petersburg Florida United States 33709
9 Tampa Florida United States 33066
10 West Palm Beach Florida United States 33407
11 Atlanta Georgia United States 30328
12 Augusta Georgia United States 30901
13 Chicago Illinois United States 60612
14 Metairie Louisiana United States 70006
15 Troy Michigan United States 48084
16 St. Louis Missouri United States 63141
17 Omaha Nebraska United States 68134
18 New Brunswick New Jersey United States 08901
19 Chapel Hill North Carolina United States 27514
20 Winston-Salem North Carolina United States 27103
21 Oklahoma City Oklahoma United States 73112
22 Danville Pennsylvania United States 17822-2920
23 Philadelphia Pennsylvania United States 19104
24 Pittsburgh Pennsylvania United States 15206
25 Carrollton Texas United States 75006
26 Carrollton Texas United States 75010
27 Colleyville Texas United States 76034
28 Dallas Texas United States 75246
29 Houston Texas United States 77030
30 Plano Texas United States 75093
31 Charlottesville Virginia United States 22903
32 Norfolk Virginia United States 23502
33 Calgary Alberta Canada T2N 4L7
34 Coquitlam British Columbia Canada V3K 3V9
35 Langley British Columbia Canada V3H 4H9
36 Winnipeg Manitoba Canada R3A 1M3
37 Winnipeg Manitoba Canada R3A 1R9
38 Kingston Ontario Canada K7L 2V7
39 Ottawa Ontario Canada K1H 7W9
40 Toronto Ontario Canada M5C 1R6
41 Toronto Ontario Canada M5G 1Z5
42 Toronto Ontario Canada M9W 4L6
43 Montreal Quebec Canada H3M 3A9
44 Montréal Quebec Canada H1T 1P6
45 Montréal Quebec Canada H2X 1N8
46 Pointe Claire Quebec Canada H9R 4S3
47 Québec Quebec Canada G1L 3L5
48 Shawinigan Quebec Canada G9N 2H6
49 Sherbrooke Quebec Canada J1H 5N4

Sponsors and Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

  • Principal Investigator: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00137371
Other Study ID Numbers:
  • 0713S5-413
First Posted:
Aug 29, 2005
Last Update Posted:
Dec 10, 2007
Last Verified:
Dec 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 10, 2007